华润双鹤董事长陆文超：全链筑基，双轮驱动开辟增长新空间

Core Viewpoint - China Resources Double Crane is strategically positioning itself for high-quality development in the pharmaceutical industry by aligning with national strategies and public health needs, focusing on a dual approach of prescription drug leadership and breakthroughs in synthetic biology [1][3]. Group 1: Strategic Development - The company has established a comprehensive product system covering multiple fields such as anti-infection, chronic diseases, and specialized areas, maintaining robust vitality amid market changes [3]. - The implementation of the national drug centralized procurement policy has provided an opportunity for the company to enhance its core capabilities, with nearly 60 products winning bids in national procurement and over 70% in provincial and alliance procurements [3][4]. - The company emphasizes cost control and efficiency in production and R&D to succeed in centralized procurement, integrating a "cost leadership" philosophy into product design [4]. Group 2: Marketing and Innovation - The marketing model has been transformed to implement differentiated promotion strategies for various products, effectively connecting the company's R&D, production, and sales capabilities [4]. - The company has addressed the challenge of narrowing profits in generic drugs and increasing R&D investment through a three-dimensional strategy of cost control, precise R&D, and model innovation [4]. - R&D investment intensity has increased from 3.7% to nearly 8%, while optimizing marketing expenses from 40% in 2019 to about 27% currently, supporting sustainable revenue and profit growth [4]. Group 3: Growth Strategy - The company aims to establish itself as "China's number one prescription drug brand" and build a second growth curve through synthetic biology, with mergers and acquisitions as a key strategy [5][7]. - Recent acquisitions, such as Henan Zhongshuai, enhance the company's capabilities in producing first-class psychotropic drugs and support high-quality generic drug development [5]. - The company has laid the groundwork for its second growth curve by integrating raw material and formulation strategies during the 14th Five-Year Plan period [6]. Group 4: Internationalization - International business is a core initiative for achieving strategic goals, with the company expanding its international network to cover over 50 countries and regions, focusing on raw material exports [8]. - The company plans to extend its internationalization efforts into formulation exports, particularly targeting the complex injection market and leveraging tax incentives from the Hainan Free Trade Zone [8][10]. - Overseas acquisitions will focus on the European and American markets, selecting targets with product differentiation advantages, while overseas licensing will serve as a means to support domestic R&D and clinical costs [10][11].